Vol. 144, No. 29 — July 17, 2010
INCOME TAX ACT
Revocation of registration of a charity
The following notice of proposed revocation was sent to the charity listed below revoking it for failure to meet the parts of the Income Tax Act as listed in this notice:
“Notice is hereby given, pursuant to paragraphs 168(1)(b) and 168(1)(e) of the Income Tax Act, that I propose to revoke the registration of the organization listed below and that the revocation of the registration is effective on the date of publication of this notice.”
|
Business Number |
Name/Address |
|---|---|
|
865677967RR0001 |
KOREAN FEDERATION OF CANADA MISSIONS SOCIETY, SURREY, B.C. |
CATHY HAWARA
Acting Director General
Charities Directorate
[29-1-o]
INCOME TAX ACT
Revocation of registration of a charity
The following notice of proposed revocation was sent to the charity listed below revoking it for failure to meet the parts of the Income Tax Act as listed in this notice:
“Notice is hereby given, pursuant to paragraphs 168(1)(b), 168(1)(d) and 168(1)(e) of the Income Tax Act, that I propose to revoke the registration of the organization listed below and that the revocation of the registration is effective on the date of publication of this notice.”
|
Business Number |
Name/Address |
|---|---|
|
119208494RR0001 |
TAMIL (SRI LANKA) REFUGEE-AID SOCIETY OF OTTAWA, OTTAWA, ONT. |
CATHY HAWARA
Acting Director General
Charities Directorate
[29-1-o]
INCOME TAX ACT
Revocation of registration of charities
Following a request from the charities listed below to have their status as a charity revoked, the following notice of intention to revoke was sent:
“Notice is hereby given, pursuant to paragraph 168(1)(a) of the Income Tax Act, that I propose to revoke the registration of the charities listed below and that by virtue of paragraph 168(2)(a) thereof, the revocation of the registration is effective on the date of publication of this notice in the Canada Gazette.”
|
Business Number |
Name/Address |
|---|---|
|
107981516RR0001 |
SIMCOE OUTREACH SERVICES INC., BARRIE, ONT. |
|
118787142RR0057 |
ALL SAINTS CHURCH, CROFTON, B.C. |
|
118800986RR0001 |
BAYVIEW FAIRWAYS SCHOOL COUNCIL, THORNHILL, ONT. |
|
118814425RR0001 |
BOYLSTON BAPTIST CHURCH, BOYLSTON, N.S. |
|
118912062RR0001 |
FAITH LUTHERAN CHURCH, PROVOST, ALTA. |
|
118970482RR0001 |
INTERNATIONAL CHURCH OF THE GOLDEN KEYS AND CHRISTIAN SCHOOL OF MENTAL SCIENCE SOCIETY, LARRY’S RIVER, N.S. |
|
118983170RR0001 |
KISBEY AND DISTRICT DONORS CHOICE APPEAL, KISBEY, SASK. |
|
119055515RR0001 |
NEW HORIZONS VILLAGE CRAFTS SOCIETY, VICTORIA, B.C. |
|
119063469RR0001 |
NOVA SCOTIA HOSPITAL FOUNDATION, DARTMOUTH, N.S. |
|
119092740RR0001 |
PHYSICALLY HANDICAPPED INDEPENDENT ADVANCEMENT COMMUNITY SERVICES, TORONTO, ONT. |
|
119098713RR0001 |
PRESBYTERIAN WOMENS MISSIONARY SOCIETY, WESTERN DIVISION, WHALLEY PRESBYTERIAN CHURCH EVENING GUILD (AFFILIATED WITH WHALLEY PRESBYTERIAN CHURCH), SURREY, B.C. |
|
119118560RR0001 |
RICHARD GORDON UTAS MEMORIAL TRUST, EDMONTON, ALTA. |
|
119145258RR0001 |
SENIOR CITIZENS SPECIAL SERVICES SOCIETY OF WEST VANCOUVER, WEST VANCOUVER, B.C. |
|
119264984RR0001 |
TIMMINS VOLUNTEER CENTRE INC., TIMMINS, ONT. |
|
119289114RR0001 |
WATERLOO MATHEMATICS FOUNDATION, WATERLOO, ONT. |
|
128325958RR0001 |
SOCIÉTÉ DE PROMOTION DE GESTION AGRICOLE DU QUÉBEC INC., SAINT-JACQUES (QC) |
|
130025877RR0001 |
VICTORIA RIGHT TO LIFE SOCIETY, VICTORIA, B.C. |
|
130387665RR0017 |
SPONSORING COMMITTEE OF NO. 618 (QUEEN CITY) SQUADRON, ROYAL CANADIAN, AIR CADETS, TORONTO, ONT. |
|
131044356RR0001 |
KELOWNA DROP-IN AND INFORMATION CENTRE, KELOWNA, B.C. |
|
131629958RR0001 |
ST. MATTHEW LUTHERAN CHURCH, STRATFORD, ONT. |
|
132331547RR0001 |
C.D. COMMUNITY CHURCH (CASTLE DOWNS), EDMONTON, ALTA. |
|
133522011RR0001 |
NORTHWEST CENTRE FOR WORLD MISSION, VANCOUVER, B.C. |
|
135038628RR0001 |
CENTRE D’ANIMATION MULTI ETHNIQUE ÉDUCATIF ROSEMONT (C.A.M.E.R.), MONTRÉAL (QC) |
|
135323772RR0001 |
HURON UNITED WAY, STRATFORD, ONT. |
|
807036298RR0001 |
JAH-JIREH SENIORS SOCIETY OF ALBERTA, RED DEER, ALTA. |
|
812895944RR0001 |
JUNK TO JOY, ALTONA, MAN. |
|
814211074RR0001 |
HABITATION L’ENVOLÉE DE BEAUCE, SAINT-GEORGES-DE-BEAUCE (QC) |
|
814661146RR0001 |
FRIENDS OF HOPE’S HOME, REGINA, SASK. |
|
834922015RR0001 |
TAXQ FOUNDATION, MISSISSAUGA, ONT. |
|
836103226RR0001 |
RIVER OF LIFE CHURCH, COQUITLAM, B.C. |
|
836486928RR0001 |
FONDATION MAISON DE RÊVES, SAINT-LAMBERT (QC) |
|
848174553RR0001 |
CAFÉ LUMIERA, MONTRÉAL (QC) |
|
849468921RR0001 |
HEAVEN’S LITTLE ANGELS FOUNDATION INC., WINNIPEG, MAN. |
|
849572755RR0001 |
DEVON COMMUNITY BEFORE AND AFTER SCHOOL CARE, DEVON, ALTA. |
|
862706769RR0001 |
BARRIER ELIMINATION ACTION CORP., TIMMINS, ONT. |
|
862996097RR0001 |
EMBRACING CHILDREN HUMANITARIAN ORGANIZATION, VICTORIA, B.C. |
|
863472940RR0001 |
CANADIAN HORSE AND PONY PROTECTION ASSOCIATION, BARRIE, ONT. |
|
869753822RR0001 |
WAINWRIGHT - THE WAY OF THE WEST PROMOTION SOCIETY, WAINWRIGHT, ALTA. |
|
869884643RR0001 |
CHARTWELL INSTITUTE FOR CARE AND COUNSELLING, OAKVILLE, ONT. |
|
870905338RR0001 |
COFFIN ISLAND LIGHTHOUSE HERITAGE SOCIETY, QUEENS COUNTY, N.S. |
|
870964673RR0001 |
FIRST NATIONS BAPTIST CHURCH, SASKATOON, SASK. |
|
871460937RR0001 |
RESTORATION COUNSELLING AND COMMUNITY SERVICES, NORTH YORK, ONT. |
|
873395578RR0001 |
COUNSEL CARE FOUNDATION, TORONTO, ONT. |
|
874005366RR0001 |
CHURCH OF DIVINE LOVE, SURREY, B.C. |
|
875248957RR0001 |
NON-PROFIT MOBILE SERVICE CORPORATION OF FORT ERIE, FORT ERIE, ONT. |
|
879059517RR0001 |
ABBOTSFORD MENNONITE FELLOWSHIP, ABBOTSFORD, B.C. |
|
883963407RR0001 |
FIRST REVIVAL PENTECOSTAL CHURCH, BELLEDUNE, N.B. |
|
885382119RR0001 |
D. BLEASDELL BOULDER PRESERVATION CORPORATION, GLEN MILLER, ONT. |
|
887847861RR0001 |
CHIU UY MEMORIAL FOUNDATION, RICHMOND, B.C. |
|
888066065RR0001 |
ST. MICHAEL AND ALL ANGELS ANGLICAN CHURCH, KISBEY, SASKATCHEWAN, KISBEY, SASK. |
|
888383833RR0001 |
THE LIGHT OF THE COUNTRY GOSPEL CHURCH, BRAMPTON, ONT. |
|
888863669RR0001 |
SPIRITUAL TEMPLE OF LIGHT SOCIETY, BURNABY, B.C. |
|
888899069RR0001 |
THE HARTFORD WELLINGTON VILLAGE HALL SOCIETY, WELLINGTON, N.S. |
|
889154241RR0001 |
KILLARNEY PARK FRIENDSHIP SOCIETY, VANCOUVER, B.C. |
|
889608378RR0001 |
LA CHAPELLE DU SACRÉ-CŒUR, MESSINES (QC) |
|
889665196RR0001 |
DRAYTON CALVIN CHRISTIAN SCHOOL FOUNDATION, MOOREFIELD, ONT. |
|
890037229RR0001 |
FONDATION T.T. BELZ/T.T. BELZ FOUNDATION, OUTREMONT (QC) |
|
890240377RR0001 |
NORTH ADDINGTON EDUCATION CENTRE COMMUNITY SCHOOL COUNCIL, CLOYNE, ONT. |
|
890811540RR0001 |
BRITISH COLUMBIA ASSOCIATION OF COVENANTING CONGREGATIONS, RICHMOND, B.C. |
|
890948243RR0001 |
ROSSEAU LAKE COLLEGE FOUNDATION, ROSSEAU, ONT. |
|
891078586RR0001 |
WOMEN’S MISSIONARY SOCIETY, ST. ANDREW’S PRESBYTERIAN CHURCH, PENTICTON, B.C., PENTICTON, B.C. |
|
891548547RR0001 |
COMITÉ DES ŒUVRES CHARITABLES DU CONSEIL STE-TRINITÉ DE GRANBY 9842-05, GRANBY (QC) |
|
891578940RR0001 |
COMITÉ DES ŒUVRES CHARITABLES DU CONSEIL DUPARQUET 3107, DUPARQUET (QC) |
|
891693442RR0001 |
SECTION CANADIENNE DU CONSEIL INTERNATIONAL DES ÉGLISES COMMUNAUTAIRES/ CANADIAN CHAPTER OF THE INTERNATIONAL COUNCIL OF COMMUNITY CHURCHES, OTTAWA (ONT.) |
|
892505454RR0001 |
FONDATION GROUPE FLEURBEC, LÉVIS (QC) |
|
892648643RR0001 |
THE CARL AND PHOEBE CONWAY FAMILY FOUNDATION, TORONTO, ONT. |
|
892912643RR0001 |
SHE’ARIM PARENTS LEAGUE, TORONTO, ONT. |
|
894538628RR0001 |
DICKINSFIELD COMMUNITY PARTNERSHIP SOCIETY, EDMONTON, ALTA. |
|
895686616RR0001 |
SMART GROWTH BRITISH COLUMBIA, VANCOUVER, B.C. |
CATHY HAWARA
Acting Director General
Charities Directorate
[29-1-o]
DECISION
Appeal No. AP-2009-003
Notice is hereby given that the Canadian International Trade Tribunal made a decision on July 2, 2010, with respect to an appeal filed by CapsCanada® Corporation from a decision of the President of the Canada Border Services Agency dated January 26, 2009, with respect to a request for re-determination pursuant to subsection 60(4) of the Customs Act.
The appeal, heard on April 20, 2010, pursuant to subsection 67(1) of the Customs Act, was dismissed.
Further information may be obtained from the Secretary, Canadian International Trade Tribunal, Standard Life Centre, 15th Floor, 333 Laurier Avenue W, Ottawa, Ontario K1A 0G7, 613-993-3595 (telephone), 613-990-2439 (fax), secretary@citt-tcce.gc.ca (email).
Ottawa, July 5, 2010
DOMINIQUE LAPORTE
Secretary
[29-1-o]
DECISION
Appeal No. AP-2009-007
Notice is hereby given that the Canadian International Trade Tribunal made a decision on July 8, 2010, with respect to an appeal filed by Sanus Systems from a decision of the President of the Canada Border Services Agency dated February 6, 2009, with respect to a request for re-determination pursuant to subsection 60(4) of the Customs Act.
The appeal, heard on June 2, 2010, pursuant to subsection 67(1) of the Customs Act, was allowed.
Further information may be obtained from the Secretary, Canadian International Trade Tribunal, Standard Life Centre, 15th Floor, 333 Laurier Avenue W, Ottawa, Ontario K1A 0G7, 613-993-3595 (telephone), 613-990-2439 (fax), secretary@citttcce.gc.ca (email).
Ottawa, July 8, 2010
DOMINIQUE LAPORTE
Secretary
[29-1-o]
DECISION
Appeal No. AP-2009-056
Notice is hereby given that the Canadian International Trade Tribunal made a decision on July 8, 2010, with respect to an appeal filed by Future Product Sales Inc. from a decision of the President of the Canada Border Services Agency dated July 22, 2009, with respect to a request for re-determination pursuant to subsection 60(4) of the Customs Act.
The appeal, heard on May 6, 2010, pursuant to subsection 67(1) of the Customs Act, was allowed.
Further information may be obtained from the Secretary, Canadian International Trade Tribunal, Standard Life Centre, 15th Floor, 333 Laurier Avenue W, Ottawa, Ontario K1A 0G7, 613-993-3595 (telephone), 613-990-2439 (fax), secretary@citt-tcce.gc.ca (email).
Ottawa, July 8, 2010
DOMINIQUE LAPORTE
Secretary
[29-1-o]
NOTICE TO INTERESTED PARTIES
The following notices are abridged versions of the Commission’s original notices bearing the same number. The original notices contain a more detailed outline of the applications, including additional locations and addresses where the complete files may be examined. The relevant material, including the notices and applications, is available for viewing during normal business hours at the following offices of the Commission:
— Central Building, Les Terrasses de la Chaudière, Room 206, 1 Promenade du Portage, Gatineau, Quebec K1A 0N2, 819-997-2429 (telephone), 994-0423 (TDD), 819-994-0218 (fax);
— Metropolitan Place, Suite 1410, 99 Wyse Road, Dartmouth, Nova Scotia B3A 4S5, 902-426-7997 (telephone), 426-6997 (TDD), 902-426-2721 (fax);
— Kensington Building, Suite 1810, 275 Portage Avenue, Winnipeg, Manitoba R3B 2B3, 204-983-6306 (telephone), 983-8274 (TDD), 204-983-6317 (fax);
— 530–580 Hornby Street, Vancouver, British Columbia V6C 3B6, 604-666-2111 (telephone), 666-0778 (TDD), 604-666-8322 (fax);
— CRTC Documentation Centre, 205 Viger Avenue W, Suite 504, Montréal, Quebec H2Z 1G2, 514-283-6607 (telephone), 283-8316 (TDD), 514-283-3689 (fax);
— CRTC Documentation Centre, 55 St. Clair Avenue E, Suite 624, Toronto, Ontario M4T 1M2, 416-952-9096 (telephone), 416-954-6343 (fax);
— CRTC Documentation Centre, Cornwall Professional Building, Room 103, 2125 11th Avenue, Regina, Saskatchewan S4P 3X3, 306-780-3422 (telephone), 306-780-3319 (fax);
— CRTC Documentation Centre, 10405 Jasper Avenue, Suite 520, Edmonton, Alberta T5J 3N4, 780-495-3224 (telephone), 780-495-3214 (fax).
Interventions must be filed with the Secretary General, Canadian Radio-television and Telecommunications Commission, Ottawa, Ontario K1A 0N2, together with proof that a true copy of the intervention has been served upon the applicant, on or before the deadline given in the notice.
Secretary General
DECISIONS
The complete texts of the decisions summarized below are available from the offices of the CRTC.
2010-418 June 30, 2010
Golden West Broadcasting Ltd.
Winnipeg, Manitoba
Approved — Renewal of the broadcasting licence for the English-language specialty radio station CFEQ-FM Winnipeg, from July 1, 2010, to August 31, 2013.
2010-419 June 30, 2010
Lighthouse Broadcasting Limited
Medicine Hat, Alberta
Approved — Renewal of the broadcasting licence for the English-language specialty radio station CJLT-FM Medicine Hat, from July 1, 2010, to August 31, 2013.
2010-420 June 30, 2010
Vista Radio Ltd.
Prince George, British Columbia
Approved — Renewal of the broadcasting licence for the English-language commercial radio station CJCI-FM Prince George, from July 1, 2010, to August 31, 2013.
2010-421 June 30, 2010
663975 B.C. Ltd.
Fort St. John, British Columbia
Approved — Renewal of the broadcasting licence for the English-language commercial radio station CKFU-FM Fort St. John, from July 1, 2010, to August 31, 2013.
Denied — Exception to the requirement to devote at least 60% of the basic annual Canadian content development contribution to FACTOR or MUSICACTION.
2010-422 June 30, 2010
Touch Canada Broadcasting (2006) Inc. (the general partner), and Touch Canada Broadcasting Inc. (the limited partner), carrying on business as Touch Canada Broadcasting Limited Partnership
Calgary, Alberta
Approved — Renewal of the broadcasting licence for the English-language specialty radio station CJSI-FM Calgary, from July 1, 2010, to August 31, 2013.
2010-423 June 30, 2010
JOCO Communications Inc.
Sturgeon Falls, Ontario
Approved — Renewal of the broadcasting licence for the English-language commercial radio station CFSF-FM Sturgeon Falls, from July 1, 2010, to August 31, 2013.
2010-424 June 30, 2010
Battlefords Tourism & Convention Association Inc.
North Battleford, Saskatchewan
Approved — Renewal of the broadcasting licence for the low-power, English-language tourist information radio station CHBT-FM North Battleford, from July 1, 2010, to August 31, 2013.
2010-425 June 30, 2010
The Haliburton Broadcasting Group Inc.
Cochrane, Ontario
Approved — Renewal of the broadcasting licence for the English-language commercial radio station CHPB-FM Cochrane, from July 1, 2010, to August 31, 2013.
2010-426 June 30, 2010
Mennonite Community Services of Southern Ontario
Aylmer, Ontario
Approved — Renewal of the broadcasting licence for the ethnic commercial radio station CHPD-FM Aylmer, from July 1, 2010, to August 31, 2013.
Denied — Amendment to a condition of licence relating to the language of broadcast so that the station may broadcast in languages other than German.
2010-427 June 30, 2010
Rogers Broadcasting Limited
Ottawa, Ontario
Approved — Renewal of the broadcasting licence for the English-language commercial radio station CISS-FM Ottawa, from July 1, 2010, to August 31, 2013.
2010-428 June 30, 2010
Canadian Hellenic Cable Radio Ltd.
Montréal, Quebec
Approved — Renewal of the broadcasting licence for the commercial ethnic FM radio station CKDG-FM Montréal, from July 1, 2010, to August 31, 2013.
2010-429 June 30, 2010
Radio CJFP (1986) ltée
Trois-Pistoles, Quebec
Approved — Renewal of the broadcasting licence for the French-language commercial radio station CIEL-FM-4 Trois-Pistoles, from July 1, 2010, to August 31, 2013.
2010-430 June 30, 2010
Radio Témiscamingue incorporée
Ville-Marie and Témiscaming, Quebec
Approved — Renewal of the broadcasting licence for the French-language commercial radio station CKVM-FM Ville-Marie and its transmitter CKVM-FM-1 Témiscaming, from July 1, 2010, to August 31, 2013.
2010-431 June 30, 2010
Radio du Golfe inc.
Sainte-Anne-des-Monts, La Martre, Mont-Louis, Les Méchins, Grande-Vallée, Gros-Morne, Cloridorme and Murdochville, Quebec
Approved — Renewal of the broadcasting licence for the French-language commercial radio station CJMC-FM Sainte-Anne-des-Monts and its transmitters, from July 1, 2010, to August 31, 2013.
2010-432 June 30, 2010
9174-8004 Québec inc.
Sainte-Marie de Beauce, Quebec
Approved — Renewal of the broadcasting licence for the French-language commercial radio station CHEQ-FM Sainte-Marie de Beauce, from July 1, 2010, to August 31, 2013.
2010-433 June 30, 2010
Jim Pattison Broadcast Group Ltd. (the general partner) and Jim Pattison Industries Ltd. (the limited partner), carrying on business as Jim Pattison Broadcast Group Limited Partnership
Prince George and Mackenzie, British Columbia
Approved — Renewal of the broadcasting licence for the English-language commercial radio station CKDV-FM Prince George and its transmitter CKMK Mackenzie, from July 1, 2010, to August 31, 2013.
2010-434 June 30, 2010
Hope FM Ministries Limited
Truro, Nova Scotia
Approved — Renewal of the broadcasting licence for the English-language specialty radio station CINU-FM Truro, from July 1, 2010, to August 31, 2013.
2010-435 June 30, 2010
CHFN Communications Society
Cape Croker (Neyaashiinigmiing), Ontario
Approved — Renewal of the broadcasting licence for the Native English- and Ojibway-language Type B radio station CHFN-FM Cape Croker, from July 1, 2010, to August 31, 2013.
2010-436 June 30, 2010
Newfoundland Broadcasting Company Limited
St. John’s, Argentia, Rattling Brook, Stephenville, Marystown, Elliston, Corner Brook, Red Rocks and Clarenville, Newfoundland and Labrador
Approved — Renewal of the broadcasting licence for the English-language commercial radio station CHOZ-FM St. John’s and its transmitters, from July 1, 2010, to August 31, 2013.
2010-437 June 30, 2010
CIAM Media & Radio Broadcasting Association
Charlie Lake and Vanderhoof, British Columbia
Fort Vermilion, Red Earth, Buffalo Head, Watt Mountain, Foggy Mountain, Weberville, Hines Creek, Slave Lake, Cleardale, Peerless Lake, Wabasca, Fort Chipewyan, Meander River, Chateh and Manning, Alberta
Buckland, Saskatchewan
Approved — Renewal of the broadcasting licence for the low-power, English-language Type B community radio programming undertaking CIAM-FM Fort Vermilion and its transmitters, from July 1, 2010, to August 31, 2013.
2010-438 June 30, 2010
Harvard Broadcasting Inc.
Regina, Saskatchewan
Approved — Renewal of the broadcasting licence for the English-language commercial radio station CKRM Regina, from July 1, 2010, to August 31, 2013.
2010-439 June 30, 2010
Harvard Broadcasting Inc.
Regina, Saskatchewan
Approved — Renewal of the broadcasting licence for the English-language commercial radio station CHMX-FM Regina, from July 1, 2010, to August 31, 2013.
2010-440 June 30, 2010
3885275 Canada Inc.
Toronto, Ontario
Approved — Renewal of the broadcasting licence for the commercial ethnic radio programming undertaking CJSA-FM Toronto, from July 1, 2010, to August 31, 2013.
2010-441 June 30, 2010
Sound of Faith Broadcasting
Kitchener-Waterloo, Ontario
Approved — Renewal of the broadcasting licence for the English-language specialty radio station CJTW-FM Kitchener, from July 1, 2010, to August 31, 2013.
2010-442 June 30, 2010
Raedio Inc.
Stratford, Ontario
Approved — Renewal of the broadcasting licence for the English-language commercial radio station CHGK-FM Stratford, from July 1, 2010, to August 31, 2013.
2010-443 June 30, 2010
United Christian Broadcasters Canada
Belleville, Cobourg, Brockville, Kingston and Bancroft, Ontario
Approved — Renewal of the broadcasting licence for the English-language commercial radio station CKJJ-FM Belleville and its transmitters, from July 1, 2010, to August 31, 2013.
2010-444 June 30, 2010
Coast Broadcasting Ltd.
St. John’s, Newfoundland and Labrador
Approved — Renewal of the broadcasting licence for the English-language commercial radio station CKSJ-FM St. John’s, from July 1, 2010, to August 31, 2013.
2010-457 July 6, 2010
La radio communautaire de LaSalle
Montréal (LaSalle Borough), Quebec
Approved — Application to change the authorized contours of the French-language Type B community radio station CKVL-FM Montréal (LaSalle Borough).
2010-458 July 6, 2010
Salt Spring Island Radio Corporation
Salt Spring Island, British Columbia
Approved — Application to change the authorized contours of the English-language commercial radio station CFSI-FM Salt Spring Island.
2010-459 July 6, 2010
Pelmorex Communications Inc.
Across Canada
Approved — Amendment to the broadcasting licence for the weather information specialty service known as The Weather Network/MétéoMédia in order to allow it to be made available for distribution in high-definition format.
2010-463 July 8, 2010
Corus Radio Company
Brampton, Ontario
The Commission finds that CFNY-FM Brampton’s broadcast of The Dean Blundell Show on March 20, 2009, did not fail to meet the objective of the Broadcasting Act that programming be of a high standard.
2010-465 July 9, 2010
Rogers Broadcasting Limited
Moncton and Saint John, New Brunswick
Approved — Applications to amend the broadcasting licences for the news/talk commercial radio stations CKNI-FM Moncton and CHNI-FM Saint John by changing the condition of licence that limits the amount of music they may broadcast.
2010-466 July 9, 2010
Rogers Broadcasting Limited
Across Canada
Approved — Application to amend the broadcasting licence for the national, English-language specialty television service known as Outdoor Life Network in order to add certain program categories to the list of program categories that may be broadcast by the service and to increase the amount of programming that may be drawn from category 7, Drama and comedy, as a whole.
Denied — Request to amend the requirements that all programming drawn from category 7 be Canadian and that programming from category 6(a), Professional sports, not include stick and ball sports.
2010-467 July 9, 2010
TVA Group Inc.
Sherbrooke, Quebec
Approved — Application to amend the broadcasting licence for CHLT-TV Sherbrooke in order to add a digital transmitter.
[29-1-o]
NOTICE OF CONSULTATION 2010-454
Notice of applications received
Various locations
Deadline for submission of interventions and/or comments: August 6, 2010
The Commission has received the following applications:
1. FDR Media Group Inc.
Across Canada
To amend the broadcasting licence for the national, third-language ethnic Category 2 specialty service known as Bollywood Times HD TV, approved in Broadcasting Decision 2010-268.
2. FDR Media Group Inc.
Across Canada
To amend the broadcasting licence for the national, third-language ethnic Category 2 specialty service known as Mehndi HD TV, approved in Broadcasting Decision 2010-270.
3. Canadian Broadcasting Corporation
Montréal, Quebec
To modify the technical parameters of CBF-FM Montréal’s rebroadcasting transmitter CBF-FM-20 Saint-Donat.
4. Canadian Broadcasting Corporation
Trois-Rivières, Quebec
To amend the broadcasting licences for the French-language FM radio stations CBF-FM-8 Trois-Rivières and CBF-FM Montréal by transferring the transmitters CBF-16 Clova, CBF-17 Lac Édouard and CBF-18 Parent from CBF-FM to CBF-FM-8.
5. Canadian Broadcasting Corporation
Ottawa, Ontario
To amend the broadcasting licence for the English-language radio station CBO-FM Ottawa by changing the frequency of the rebroadcasting transmitter CBOB-FM Brockville.
July 5, 2010
[29-1-o]
NOTICE OF CONSULTATION 2010-464
Notice of applications received
Various locations Deadline for submission of interventions and/or comments: August 12, 2010
The Commission has received the following applications:
1. TVA Group Inc.
Québec, Quebec
To amend the broadcasting licence for the French-language television station CFCM-TV Québec in order to add a digital transmitter at Québec to broadcast the programming of CFCM-TV, in the digital format.
2. 1486781 Ontario Limited
Brantford, Ontario
To effect a change to the effective control of 1486781 Ontario Limited through the transfer of all of its issued and outstanding shares from its sole shareholder, Anthony Schleifer, to Durham Radio Inc., pursuant to subsection 11(4) of the Radio Regulations, 1986.
3. 1486781 Ontario Limited
Brantford, Ontario
To amend the broadcasting licence for the English-language specialty FM radio station CFWC-FM Brantford in order to delete conditions of licence relating to the broadcast of musical selections and in order to offer a broad-based rock format.
July 8, 2010
[29-1-o]
NOTICE OF CONSULTATION 2010-468
Notice of application received
Halifax and Sydney, Nova Scotia; Moncton and Saint John, New Brunswick; Montréal, Quebec; Ottawa, Toronto, Kitchener, Sudbury, Timmins, North Bay and Sault Ste. Marie, Ontario; Winnipeg, Manitoba; Saskatoon, Regina, Prince Albert and Yorkton, Saskatchewan; Calgary, Lethbridge and Edmonton, Alberta; and Vancouver, British Columbia
Deadline for submission of interventions and/or comments: August 13, 2010
The Commission has received the following application:
1. CTVglobemedia Inc., on behalf of its wholly owned subsidiary CTV Television Inc.
Halifax and Sydney, Nova Scotia; Moncton and Saint John, New Brunswick; Montréal, Quebec; Ottawa, Toronto, Kitchener, Sudbury, Timmins, North Bay and Sault Ste. Marie, Ontario; Winnipeg, Manitoba; Saskatoon, Regina, Prince Albert and Yorkton, Saskatchewan; Calgary, Lethbridge and Edmonton, Alberta; and Vancouver, British Columbia
To amend the broadcasting licences for various television stations in regard to the broadcast of Canadian programs.
July 9, 2010
[29-1-o]
BOUNDARY WATERS TREATY OF 1909
Review of the bi-national management of the Lake of the Woods and Rainy River Basin
By letters dated June 17, 2010, the governments of Canada and the United States asked the International Joint Commission (IJC) to examine and make recommendations regarding the bi-national management of the Lake of the Woods and Rainy River Basin system and the IJC’s potential role in this management.
This review would serve to complement government activities that foster trans-jurisdictional coordination and collaboration on science and management activities to enhance and restore water quality in the basin. It would also contribute to any future approach to addressing new and emerging water quality issues and water management needs. A final report is expected to be released by the end of 2011. In the meantime, the IJC will make periodic reports to the governments that will include plans for engaging with federal governments and relevant provinces, First Nations, tribes and states, as well as the wider body of stakeholders and the public. The IJC anticipates holding public consultations on this matter at dates and locations to be announced in the local news media and on the IJC’s Web site.
In addition to the public hearings, the IJC invites all interested parties to submit written comments over the course of this review to the addresses below:
Secretary, Canadian Section
234 Laurier Avenue W
22nd Floor
Ottawa, Ontario K1P 6K6
Fax: 613-993-5583
Email: Commission@ottawa.ijc.org
Secretary, United States Section
2000 L Street, Suite 615
Washington, DC 20440
Fax: 202-632-2007
Email: Commission@washington.ijc.org
The International Joint Commission is a bi-national Canada–United-States organization established by the Boundary Waters Treaty of 1909. It assists the governments in managing waters along the border for the benefit of both countries in a variety of ways including examining issues referred to it by the two federal governments.
More information, including the full text of the governments’ letters of reference, may be found on the Commission’s Web site, at www.ijc.org.
[29-1-o]
NOTICE AND COMMENT ISSUED BY THE PATENTED MEDICINE PRICES REVIEW BOARD ON JUNE 18, 2010, FOR FASLODEX®
TAKE NOTICE that the Vice-Chairperson of the Patented Medicine Prices Review Board (“Board” or “PMPRB”) proposes to accept a Voluntary Compliance Undertaking (VCU) in respect of the price of the medicine FASLODEX. AND TAKE NOTICE that written submissions in respect of the proposed Voluntary Compliance Undertaking will be considered.
A. Purpose of this Notice
1. The purpose of this Notice is to provide Ministers of Health in the provinces and territories of Canada and other interested persons with an opportunity to make submissions on the appropriateness of accepting a Voluntary Compliance Undertaking in the form set out in Attachment 1 with respect to the price proposed by AstraZeneca Canada Inc. (“AstraZeneca”) for the patented medicine FASLODEX®.
B. Background
2. FASLODEX is indicated for the hormonal treatment of locally advanced or metastatic breast cancer in po.3st-menopausal women, regardless of age, who have disease progression following prior endocrine therapy. It is supplied in a pre-filled syringe in a strength of 50 mg/mL and is administered at monthly intervals as a single 5 mL intramuscular injection.
3. Canadian Patent No. 2,351,004 pertaining to FASLODEX was granted to AstraZeneca AB, Sweden on February 18, 2003 and will expire on January 8, 2021. AstraZeneca is the patentee for the purposes of the PMPRB.
4. Health Canada issued a Notice of Compliance (NOC) to AstraZeneca for FASLODEX on February 17, 2004 (DIN 02248624). FASLODEX was first sold in Canada on February 1, 2006.
5. Pursuant to sub-section 85 (1) of the Patent Act (Act), and for purposes of determining whether the price of a patented medicine is excessive under section 83, the Board shall take into consideration the following factors, to the extent that information on such factors is available to the Board:
a. the prices at which the medicine has been sold in the relevant market;
b. the prices at which other medicines in the same therapeutic class have been sold in the relevant market;
c. the prices at which the medicine and other medicines in the same therapeutic class have been sold in countries other than Canada;
d. changes in the Consumer Price Index; and
e. such other factors as may be specified in any regulations made for the purposes of this subsection.
6. Based on the Board’s previous Excessive Price Guidelines (pre-2010 Guidelines), the Human Drug Advisory Panel (HDAP) recommended that FASLODEX pre-filled syringes be classified as a category 3 new drug product (provides moderate, little or no therapeutic advantage over comparable existing drug products). The HDAP also identified the oral therapies TAMOFEN (tamoxifen), ARIMIDEX® (anastrozole), FEMARA (letrozole), AROMASIN (exemestane) and MEGACE (megestrol) as comparable drug products, as they share the same indication and are used in the treatment of patients with hormonereceptor positive advanced or metastatic breast cancer.
7. In considering whether the introductory price of a category 3 new drug product appears excessive, one of the tests under the PMPRB’s pre-2010 Guidelines is whether it exceeds the prices of the comparable drug products in the same therapeutic class (Therapeutic Class Comparison (TCC) test). Based on the TCC test, the introductory maximum non-excessive (MNE) price was $161.1990 (Attachment 2).
8. A second test under the pre-2010 Guidelines is whether the Canadian price of the new drug product exceeds the prices of that drug in the countries listed in the Patented Medicines Regulations (Regulations). (see footnote 1) FASLODEX is sold in all seven comparator countries. Prices in these countries at the time of introduction ranged from $616.3043 (Italy) to $962.7268 (United States). The median international price was $692.2303. The Canadian price was $600.00, lower than the price of FASLODEX in all seven of the PMPRB reference countries.
9. The introductory MNE price ($161.1990) based on therapeutically comparable drugs in Canada is considerably lower (73.4% lower) than the lowest price in the comparator countries listed in the Regulations. Attachment 3 provides details of the international prices.
10. The price of FASLODEX in Canada has remained constant at $600.0000 since introduction in 2006.
11. FASLODEX is sold to a very small population of Canadian women to respond to their very specific needs. The market share of FASLODEX in Canada relative to the other hormonal therapies identified as therapeutic class comparators during the introductory period was very minimal (0.005%), and as units of sale have not increased measurably from the introductory period, its market share among the hormonal therapies has not grown appreciably during subsequent periods of sale (Attachment 4).
12. Section 85 of the Act identifies a comparison of the prices at which the medicine and other medicines in the same therapeutic class have been sold in countries other than Canada as one factor which the Board must take into account in its deliberation in contemplation of a remedial order.
13. It is within the Board’s discretion to ascribe the weight it deems appropriate to prices at which the medicine and other medicines in the same therapeutic class have been sold in countries other than Canada when considering the particular circumstances of any matter upon which it is adjudicating. The pre-2010 Guidelines do not provide for the International Therapeutic Class Comparison (ITCC) test, but the Board Guidelines which were implemented January 1, 2010 do in the context of an investigation for information purposes.
14. In light of the circumstances of this case, Board Staff has recommended that it is appropriate to rely on a ratio approach ITCC test. The ratio approach ITCC test was previously used in the HUMALOG (insulin lispro) and VIREAD (tenofovir disoproxil fumarate) cases in determining whether the prices were within the Guidelines.
15. Although MEGACE was the highest priced comparator in the domestic TCC test for FASLODEX, ARIMIDEX has the largest share of market sales and is also sold by AstraZeneca. As well, in two randomised clinical trials, ARIMIDEX has been compared to FASLODEX and determined to be clinically equivalent when used as second line hormonal therapy. Applying the median international ratio of FASLODEX to ARIMIDEX under the ITCC test to the price of ARIMIDEX in Canada would yield an introductory MNE price (now known as the maximum average potential price (MAPP)) of $521.2350 for FASLODEX (Attachment 5).
16. Board Staff and AstraZeneca are proposing that the ITCC test be used to set the introductory MNE price for FASLODEX at $521.2350, rather than using the TCC test result ($161.1990). On this basis, AstraZeneca and Board Staff have also agreed on a VCU (Attachment 1). Subject to the outcome of this Notice and Comment it is recommended that this VCU be accepted by the Vice-Chairperson.
C. Process for Submissions
17. All persons who wish to make representations in this matter shall file a written submission with the Board on or before September 17, 2010.
18. All submissions by the provincial and territorial Ministers of Health will be considered by the Board.
19. All submissions by other persons shall include a clear statement of the person’s interest in this matter, and shall state the reasons why the Board should consider the submission.
20. All submissions shall be filed with the Director, Board Secretariat at Box L40, 333 Laurier Avenue West, Suite 1400, Ottawa, Ontario K1P 1C1. Further information on the role and process of the Board may also be obtained from the Director, Board Secretariat.
21. Board Staff and AstraZeneca will be given the opportunity to make written submissions to the Board in response to any written submissions received within fifteen (15) days thereafter, no later than October 1, 2010.
22. The Vice-Chairperson will consider all submissions in determining whether to accept the proposed Voluntary Compliance Undertaking.
23. The Vice-Chairperson’s decision and all submissions will be posted on the PMPRB Web site.
Ottawa, June 11, 2010
D. Table of Contents
1. FASLODEX: Attachment 1 — Voluntary Compliance Undertaking
2. FASLODEX: Attachment 2 — Therapeutic Class Comparison
3. FASLODEX: Attachment 3 — International Price Comparison
4. FASLODEX: Attachment 4 — Market Shares of Faslodex and its Comparators
5. FASLODEX: Attachment 5 — International Therapeutic Class Comparison
Attachment 1 — Voluntary Compliance Undertaking
Voluntary Compliance Undertaking of AstraZeneca Canada Inc. to the Patented Medicine Prices Review Board
1.0 Product Summary
1.1 FASLODEX® (fulvestrant) is indicated for the hormonal treatment of locally advanced or metastatic breast cancer in post menopausal women, regardless of age, who have disease progression following prior endocrine therapy. It is supplied as a pre-filled syringe with a strength of 50 mg/mL and is administered at monthly intervals as a single 5 mL intramuscular injection.
1.2 Health Canada issued a Notice of Compliance (NOC) to AstraZeneca Canada Inc. (AstraZeneca) for FASLODEX on February 17, 2004 (DIN 02248624). FASLODEX was first sold in Canada on February 1, 2006.
1.3 Canadian Patent No. 2,351,004 pertaining to FASLODEX was granted to AstraZeneca AB, Sweden on February 18, 2003 and will expire on January 8, 2021. AstraZeneca is the patentee for the purposes of the Patented Medicines Prices Review Board (PMPRB).
2.0 Application of the Excessive Price Guidelines
2.1 The PMPRB’s Human Drug Advisory Panel (HDAP) recommended that FASLODEX be classified as a category 3 new drug product and identified oral hormonal treatments, namely, Tamofen (tamoxifen), ARIMIDEX® (anastrozole), Femara (letrozole), Aromasin (exemestane), and Megace (megestrol), as the most appropriate comparator drug products.
2.2 In accordance with the Board’s Excessive Price Guidelines (Guidelines), a Therapeutic Class Comparison (TCC) test and an International Price Comparison (IPC) test were conducted. The result of the TCC test indicated that the introductory price of $600.00 appeared to exceed the Guidelines as it was above the maximum non-excessive (MNE) price of $161.1990. The result of the IPC test indicated that the Canadian price was lower than the corresponding prices of FASLODEX in all seven of the PMPRB reference countries outlined in the Regulations.
2.3 The price of FASLODEX in Canada has remained constant at $600.0000 since it was first sold in 2006.
2.4 The Board’s Notice and Comment dated June 11, 2010 provides the details for the rationale and background information surrounding the application of the ratio approach International Therapeutic Class Comparison (ITCC) test for FASLODEX.
2.5 ARIMIDEX (anastrozole) has the largest share of market sales, is sold by AstraZeneca in Canada and is sold in all seven of the PMPRB reference countries. Applying the median international ratio of FASLODEX to ARIMIDEX under the ITCC test to the price of ARIMIDEX in Canada would yield an introductory MNE price of $521.2350. Cumulative excess revenues calculated by Board Staff as having been received by AstraZeneca as a result of selling FASLODEX at a price above the MNE price were $405,030.29 as of December 31, 2009.
3.0 Position of the Patentee
3.1 This Voluntary Compliance Undertaking (VCU) constitutes no admission by AstraZeneca that the price in Canada of FASLODEX is now, or was at any time since the date of the first sale of the medicine, excessive for purposes of the Patent Act.
3.2 AstraZeneca will not be bound by the undertaking herein unless this VCU is accepted by the Board.
4.0 Terms of the Voluntary Compliance Undertaking
4.1 In order to comply with the Guidelines, AstraZeneca agrees to undertake the following:
4.1.1 To agree that the MNE prices of FASLODEX are as follows:
2006 — $521.2350
2007 — $532.1809
2008 — $544.6906
2009 — $546.7755
2010 — $558.7899
4.1.2 To reduce the price of FASLODEX within 30 days of the acceptance of this VCU so that it does not exceed the 2010 MNE price of $558.7899;
4.1.3 To offset the cumulative excess revenues received from February 2006 to December 31, 2009 by making a payment to Her Majesty in right of Canada in the amount of $405,030.29 within 30 days of the acceptance of the VCU;
4.1.4 To offset any excess revenues received during the period January 1, 2010 to the date of reduction of the price of FASLODEX as per 4.1.1 of this VCU by making a payment within 30 days of the filing of semi-annual price and sales data as required by the Patented Medicines Regulations in the amount of the excess revenues, as calculated by Board Staff, received as a result of selling FASLODEX at a price in excess of the 2010 MNE price set out in sub-paragraph 4.1.1 above;
4.1.5 Within 15 days of acceptance of this VCU, to provide notification to customers of the price reductions for FASLODEX and that this price reduction is the result of an undertaking to the PMPRB, to provide a reference to the PMPRB Web site for the complete text of the VCU, and to provide copies of such notifications to Board Staff;
4.1.6 To file evidence with Board Staff within 30 days of the acceptance of this VCU that the price of FASLODEX has been reduced in a manner consistent with the terms of this VCU; and
4.1.7 To ensure that the price of FASLODEX remains within the Guidelines in all future periods in which FASLODEX is under the PMPRB’s jurisdiction.
AstraZeneca Canada Inc. Signature: Original signed by Company Officer: Marion E. McCourt Position: President and CEO Date: June 11, 2010
Attachment 2 — Therapeutic Class Comparison
Therapeutic Class Comparison
| Strength |
Dosage Regime |
Unit Price |
Cost per 30 Day Treatment |
|
|---|---|---|---|---|
Faslodex (fulvestrant) |
250 mg/5 mL |
1 vial every 30 days |
600.00001 |
600.0000 |
Tamofen (tamoxifen) |
20 mg |
1 tab daily x30 days |
0.35002 |
10.5000 |
Arimidex (anastrozole) |
1 mg |
1 tab daily x30 days |
4.95002 |
148.5000 |
Femara (letrozole) |
2.5 mg |
1 tab daily x30 days |
4.95002 |
148.5000 |
Aromasin (exemestane) |
25 mg |
1 tab daily x30 days |
4.95002 |
148.5000 |
Megace (megestrol) |
160 mg |
1 tab daily x30 days |
5.37332 |
161.1990 |
Megace (megestrol) |
40 mg |
4 tab daily x30 days |
1.34302 |
161.1600 |
Notes:
1 Publicly available ex-factory price as per Patented Medicines Regulations
2 Ontario Drug Benefit Formulary 2005 & September 2006
Highest allowable unit price based on cost per treatment $161.1990 of Megace 160 mg
Attachment 3 — International Price Comparison
International Price Comparison
Faslodex (250 mg/5 mL Syringe)
International Prices1
January-June 2006
(Cdn $)4
| Country |
Price per 250 mg/5 mL Syringe |
|---|---|
Canada |
$600.0000 |
Germany |
$693.6503 |
France |
$692.2303 |
Italy |
$616.3043 |
Sweden |
$624.9171 |
Switzerland |
$664.9642 |
UK |
$737.3052 |
US2,3 |
$962.7268 |
Median |
$692.2303 |
1 Sources for Prices:
Canada: Publicly available ex-factory price as per Patented Medicines Regulations Germany: Rote Liste, January 2006 France: Sempex, February 2006 Italy: L’informatore farmaceutico, June 2006 Sweden: Prislista, June 2006 Switzerland: Medwin website, January-June 2006 UK: Mims, June 2006 US: Federal Supply Schedule (FSS), January-June 2006 Thomson Micromedex Wholesale Acquisition Cost (WAC), April 2006
2 The methodology for deriving net backed-out price can be found in the study, “Verification of Foreign Patented Drug Prices 2000” available on the PMPRB Web site www.pmprb-cepmb.gc.ca under Other Publications; Study Series
3 For the US, there is no national drug formulary, nor regulated mark-ups. The Red Book publishes a Direct Price (DP); the Federal Supply Schedule (FSS) includes a drug formulary for purposes of several federal drug plans and represents the prices paid by the U.S. Government. Thomson Micromedex publishes a Wholesale Acquisition Cost (WAC). For purposes of this comparison, the U.S. price has been estimated by averaging the WAC and FSS
4 Exchange rates based on 36-months ending June 2006 as per PMPRB Compendium Schedule 3
| Country |
Exchange Rate |
|---|---|
Canada |
1.00000000 |
Germany |
1.53510000 |
France |
1.53510000 |
Italy |
1.53510000 |
Sweden |
0.16695556 |
Switzerland |
0.99106389 |
UK |
2.24159444 |
US |
1.25196111 |
Attachment 4 — Market Shares of Faslodex and its Comparators
Market Shares of Faslodex and its Comparators
Introductory Period
January-June 2006 Period
| Units |
Sales Revenue |
Unit Price |
% of Market Share |
|
|---|---|---|---|---|
Faslodex 250 mg/5 mL syringe |
300.0 |
$169,000.00 |
$563.3333 |
0.005% |
Tamofen 20 mg/tab |
270,000.0 |
$94,000.00 |
$0.3481 |
4.3% |
Arimidex 1 mg/tab |
3,447,000.0 |
$17,577,000.00 |
$5.0992 |
54.6% |
Femara 2.5 mg/tab |
1,878,000.0 |
$10,050,000.00 |
$5.3514 |
29.7% |
Aromasin 25 mg/tab |
687,000.0 |
$3,541,000.00 |
$5.1543 |
10.9% |
Megace 160 mg/tab |
36,000.0 |
$115,000.00 |
$3.1944 |
0.6% |
Total |
6,318,300.0 |
$31,546,000.00 |
$582.4809 |
100.0% |
Note: IMS, June 2006
January-December 2006 Period
| Units |
Sales Revenue |
Unit Price |
% of Market Share |
|
|---|---|---|---|---|
Faslodex 250 mg/5 mL syringe |
1,000.0 |
$647,000.00 |
$647.0000 |
0.007% |
Tamofen 20 mg/tab |
528,000.0 |
$186,000.00 |
$0.3523 |
3.9% |
Arimidex 1 mg/tab |
7,335,000.0 |
$37,416,000.00 |
$5.1010 |
54.6% |
Femara 2.5 mg/tab |
4,032,000.0 |
$21,623,000.00 |
$5.3628 |
30.0% |
Aromasin 25 mg/tab |
1,467,000.0 |
$7,585,000.00 |
$5.1704 |
10.9% |
Megace 160 mg/tab |
60,000.0 |
$6,990,000.00 |
$116.5000 |
0.4% |
Total |
13,423,000.0 |
$74,447,000.00 |
$779.4866 |
100.0% |
Note: IMS, December 2006
Market Shares of Faslodex and its Comparators for the 2007 to 2009 Periods
2007
| Units |
Sales Revenue |
Unit Price |
% of Market Share |
|
|---|---|---|---|---|
Faslodex 250 mg/5 mL syringe |
1,600.0 |
$984,000.00 |
$615.0000 |
0.011% |
Tamofen 20 mg/tab |
426,000.0 |
$153,000.00 |
$0.3592 |
2.8% |
Arimidex 1 mg/tab |
8,265,000.0 |
$42,213,000.00 |
$5.1074 |
54.3% |
Femara 2.5 mg/tab |
4,839,000.0 |
$26,169,000.00 |
$5.4079 |
31.8% |
Aromasin 25 mg/tab |
1,662,000.0 |
$8,582,000.00 |
$5.1637 |
10.9% |
Megace 160 mg/tab |
24,000.0 |
$131,000.00 |
$5.4583 |
0.2% |
Total |
15,217,600.0 |
$78,232,000.00 |
$636.4965 |
100.0% |
Note: IMS, December 2007
2008
| Units |
Sales Revenue |
Unit Price |
% of Market Share |
|
|---|---|---|---|---|
Faslodex 250 mg/5 mL syringe |
1,800.0 |
$1,098,000.00 |
$610.0000 |
0.011% |
Tamofen 20 mg/tab |
345,000.0 |
$124,000.00 |
$0.3594 |
2.2% |
Arimidex 1 mg/tab |
9,057,000.0 |
$46,393,000.00 |
$5.1223 |
57.2% |
Femara 2.5 mg/tab |
4,626,000.0 |
$31,202,000.00 |
$6.7449 |
29.2% |
Aromasin 25 mg/tab |
1,782,000.0 |
$9,194,000.00 |
$5.1594 |
11.3% |
Megace 160 mg/tab |
21,000.0 |
$139,000.00 |
$6.6190 |
0.1% |
Total |
15,832,800.0 |
$88,150,000.00 |
$634.0051 |
100.0% |
Note: IMS, December 2008
2009(1)
| Units |
Sales Revenue |
Unit Price |
% of Market Share |
|
|---|---|---|---|---|
Faslodex 250 mg/5 mL syringe |
800.0 |
$553,000.00 |
$691.2500 |
0.009% |
Tamofen 20 mg/tab |
147,000.0 |
$53,000.00 |
$0.3605 |
1.7% |
Arimidex 1 mg/tab |
4,587,000.0 |
$23,560,000.00 |
$5.1363 |
53.3% |
Femara 2.5 mg/tab |
2,997,000.0 |
$16,852,000.00 |
$5.6230 |
34.8% |
Aromasin 25 mg/tab |
873,000.0 |
$4,500,000.00 |
$5.1546 |
10.1% |
Megace 160 mg/tab |
- |
- |
- |
- |
Total |
8,604,800.0 |
$45,518,000.00 |
$707.5244 |
100.0% |
Notes: IMS, June 2009
Megace 160 mg was reported as having less than a 1000 units sold (-)
Megace 40 mg was not reported in IMS during any period
Market Shares of Faslodex and Arimidex
January-December 2007 Period
| Units |
Sales Revenue |
Unit Price |
% of Market Share |
|
|---|---|---|---|---|
Faslodex 250 mg/5 mL syringe |
1,600.0 |
$984,000.00 |
$615.0000 |
0.02% |
Arimidex 1 mg/tab |
8,265,000.0 |
$42,213,000.00 |
$5.1074 |
99.98% |
Total |
8,266,600.0 |
$43,197,000.00 |
- |
100.00% |
January-December 2008 Period
| Units |
Sales Revenue |
Unit Price |
% of Market Share |
|
|---|---|---|---|---|
Faslodex 250 mg/5 mL syringe |
1,800.0 |
$1,098,000.00 |
$610.0000 |
0.02% |
Arimidex 1 mg/tab |
9,057,000.0 |
$46,393,000.00 |
$5.1223 |
99.98% |
Total |
9,058,800.0 |
$47,491,000.00 |
- |
100.00% |
January-June 2009 Period
| Units |
Sales Revenue |
Unit Price |
% of Market Share |
|
|---|---|---|---|---|
Faslodex 250 mg/5 mL syringe |
800.0 |
$553,000.00 |
$691.2500 |
0.02% |
Arimidex 1 mg/tab |
4,587,000.0 |
$23,560,000.00 |
$5.1363 |
99.98% |
Total |
4,587,800.0 |
$24,113,000.00 |
- |
100.00% |
Note: IMS, (Dec 2007, Dec 2008 & Jun 2009) information was used for this table, which captures Hospital & Pharmacy markets only
Attachment 5 — International Therapeutic Class Comparison
International Therapeutic Class Comparison
Faslodex 250 mg/mL (DIN 02248624) Pricing Ratios in Canada and Other Countries1 Using Backed-Out2 International Formulary Prices for Faslodex and Comparators Cost per Treatment in Canadian Currency3 (Based on Date of First sale: February 2006)
| Canada |
France |
Germany |
Italy |
Sweden |
|
|---|---|---|---|---|---|
Faslodex 250 mg/mL |
$600.0000 |
$633.5178 |
$694.8106 |
$605.6430 |
$638.8639 |
Arimidex 1 mg (30 mg) |
$148.5000 |
$220.4640 |
$211.5360 |
$162.9060 |
$181.7700 |
Switzerland |
UK |
US |
Equivalent Canadian Faslodex price |
|
|---|---|---|---|---|
Faslodex 250 mg/mL |
$694.4976 |
$709.1020 |
$1,028.5746 |
|
Arimidex 1 mg (30 mg) |
$242.7780 |
$149.5620 |
$271.6770 |
$521.2350 |
Notes:
1 Sources for Prices:
All Faslodex and Arimidex prices taken from publicly available ex-factory price as per Patented Medicines Regulations. All comparators taken from public sources.
Canada: Ontario Drug Benefit Formulary, September 2006, Quebec February 2006
Germany: Rote Liste, January 2006
France: Sempex, February 2006
Italy: L’informatore farmaceutico, June 2006
Sweden: Prislista, June 2006
Switzerland: Medwin website, January-June 2006
UK: Mims, June 2006
US: Federal Supply Schedule (FSS), January-June 2006
Thomson Micromedex Wholesale Acquisition Cost (WAC), April 2006
2 The methodology for deriving net backed-out price can be found in the study, “Verification of Foreign Patented Drug Prices 2000” available on the PMPRB Web site www.pmprb-cepmb.gc.ca under Other Publications; Study Series
3 Exchange rates based on 36-months ending September 2005 as per PMPRB Compendium Schedule 3
| September 2005 36-month Exchange Rates |
|
|---|---|
Country |
Exchange Rate |
Canada |
1.00000000 |
Germany |
1.58379444 |
France |
1.58379444 |
Italy |
1.58379444 |
Sweden |
0.17323056 |
Switzerland |
1.03508056 |
UK |
2.32690833 |
US |
1.33759167 |
PUBLIC SERVICE EMPLOYMENT ACT
Permission granted
The Public Service Commission of Canada, pursuant to section 116 of the Public Service Employment Act, hereby gives notice that it has granted permission, pursuant to subsection 115(2) of the said Act, to Melanie Fay Baete, Fire Rescue Technician (FR-01), Canadian Forces Base Shilo, Department of National Defence, Shilo, Manitoba, to be a candidate, before and during the election period, for the position of Member of the Local Urban District for the Town of Holland, Rural Municipality of Victoria, Manitoba, in a municipal election to be held on October 27, 2010.
July 6, 2010
KATHY NAKAMURA
Director General
Political Activities Directorate
[29-1-o]
Footnote 1
France, Germany, Italy, Sweden, Switzerland, the United Kingdom and the United States
NOTICE:
The format of the electronic version of this issue of the Canada Gazette was modified in order to be compatible with extensible hypertext markup language (XHTML 1.0 Strict).